Skip to content
lifestyle.ketodash.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
MBX Biosciences, Inc.
MBX Biosciences Appoints Jeff Held Chief Legal Officer
September 8, 2026
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
August 27, 2026
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 6, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
May 19, 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
March 10, 2026
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 9, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 9, 2026
MBX Biosciences to Participate in Upcoming Investor Conferences
February 13, 2026